Medindia

X

The Continued Uptake of Interleukin Inhibitors and TNF-alpha Inhibitors and Increasing Penetration of Biologics Will Drive the Psoriasis Drug Market to Double to $6.8 Billion in 2019

Monday, August 9, 2010 Drug News J E 4
Advertisement
Amgen/GlaxoSmithKline/Pfizer/Takeda's Enbrel Will Face Stiff Competition From Abbott/Eisai's Humira and the Interleukin Inhibitors, According to Findings from Decision Resources

For more information, contact:

Decision Resources, Inc.

Lisa Osgood

781-296-2606

losgood@hl-isy.com

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Driven Primarily by the Uptake of Human Genome Sci...
S
Americans' Confidence in Their Ability to Access a...